Polynucleotide injectables are one of the fastest-growing categories in regenerative aesthetics. Unlike dermal fillers, which add volume, or neuromodulators, which relax muscles, polynucleotides work at the cellular level — delivering purified DNA fragments that stimulate fibroblasts to produce new collagen, improve extracellular matrix quality, and reduce inflammation. The result is not a reshaped face but a biologically healthier one.
This article covers how polynucleotides work, what the clinical evidence says, how they are administered, what they cost, and how they compare to PRP, exosomes, and other regenerative injectables.
What polynucleotides are and where they come from
Polynucleotides (PN) are long-chain biopolymers made of nucleotide monomers — the same building blocks as DNA. In aesthetic medicine, the polynucleotides used in injectable products are derived from salmon sperm or roe, processed through multi-stage purification to remove immunogenic proteins. The result is a highly purified, biocompatible DNA fragment preparation that can be injected into the dermis without triggering an immune reaction.
The use of polynucleotides in medicine is not new. A specific fraction called polydeoxyribonucleotide (PDRN) has been used in wound healing, ophthalmology, and orthopedics for over 30 years. Its aesthetic application — injecting PDRN or broader polynucleotide preparations into the skin to improve texture, hydration, and elasticity — has grown rapidly since 2019, driven by results from clinical studies and the broader trend toward regenerative aesthetics.
The key products in this category include Plinest, Rejuran, Nucleofill, Vitaran, and PhilArt. Most are classified as medical devices in Europe and hold CE marking. None have FDA approval in the United States.
How polynucleotides work in the skin
Polynucleotides act through several complementary mechanisms:
1. Fibroblast stimulation. The DNA fragments provide nucleotides that fibroblasts use for cellular repair and proliferation. Activated fibroblasts increase production of type I and type III collagen, the primary structural proteins in the dermis. This rebuilds the extracellular matrix from within.
2. Extracellular matrix remodeling. Beyond collagen, polynucleotides stimulate synthesis of other structural proteins and ground substance, improving dermal density and skin firmness over time. A study in the Journal of Cosmetic Dermatology (2020) found measurable improvements in dermal density and elasticity in photoaged skin after polynucleotide treatment.
3. Anti-inflammatory effects. Polynucleotides modulate inflammatory pathways, reducing the chronic low-grade inflammation that contributes to skin aging. This makes them particularly suitable for inflamed or compromised skin — including post-procedure recovery and conditions like rosacea.
4. Hydration. The molecular structure of polynucleotides is strongly hydrophilic. They attract and bind water molecules, improving tissue hydration and skin turgor. Clinical measurements show increased skin hydration lasting weeks to months after treatment.
5. Tissue repair signaling. The A2A adenosine receptor pathway, which PDRN specifically activates, promotes angiogenesis and tissue regeneration. This receptor-mediated mechanism is distinct from the mechanical effects of HA fillers or the growth-factor approach of PRP.
The combination of these mechanisms produces gradual, cumulative improvement rather than an instant change. Patients typically notice improved skin texture and brightness within 2–4 weeks, with continued collagen production over 2–3 months.
What the clinical evidence shows
The evidence base for polynucleotides in aesthetics has expanded significantly. Key findings:
A 2026 real-world study published in the Journal of Cosmetic Dermatology (PMCID: PMC12759169) evaluated injectable polynucleotides with high purification technology (PN HPT) in 168 aesthetic patients across face, neck, and decollete treatments. Results showed visible improvement in 100% of facial treatments, with 53.5% rated as "marked" or "excellent." For the neck, moderate to significant improvements were observed in over 93% of cases. Patient satisfaction ranged from 97% to 100%. No serious adverse events occurred.
A 2024 literature review published in PMC (PMCID: PMC11311621) analyzed 14 studies on polynucleotide efficacy for skin rejuvenation. The review found evidence supporting polynucleotides for improving skin texture, hydration, elasticity, and wrinkle reduction across multiple treatment areas including the face, neck, and periorbital region.
A clinical study combining hyaluronic acid with polynucleotides found measurable improvements at 12 weeks: +31% hydration, +22% elasticity, and a 19% reduction in skin roughness.
A study by Kim et al. evaluating polynucleotides for lateral canthal lines (crow's feet) in 20 patients showed significant improvements in wrinkle depth and skin elasticity at 1, 3, and 6 months after a single treatment, with no serious adverse events.
Lis et al. investigated polynucleotides for neck skin aging, comparing single high-dose and multiple low-dose injection regimens. Both approaches improved skin appearance, but the multiple-injection protocol produced more sustained results.
A Lee et al. (2020) study specifically demonstrated strong evidence for topical and intradermal polynucleotide administration for peri-orbital rejuvenation — one of the most in-demand treatment areas where thin skin makes filler risky.
How treatment is administered
Polynucleotide injections are typically performed using a serial puncture or linear threading technique with a fine needle (30–32G) or cannula. The product is injected into the superficial to mid-dermis.
Protocol: A standard course consists of 3–4 sessions spaced 2–3 weeks apart. Each session takes approximately 20–30 minutes. Topical anesthetic is usually applied 20–30 minutes beforehand.
Treatment areas: Face (especially periorbital area, cheeks, forehead), neck, decollete, and hands. The periorbital area is a particular strength of polynucleotides because the thin skin in this region is poorly served by fillers, which carry higher risks of lumps, Tyndall effect, and vascular complications.
Downtime: Minimal. Patients may experience redness, swelling, or small papules at injection sites that resolve within 24–48 hours. Bruising is possible but typically mild.
Results timeline: Initial improvements in hydration and brightness appear within 1–2 weeks. Collagen-mediated improvements in texture, firmness, and wrinkle reduction become visible at 4–6 weeks and continue to build for 2–3 months after the final session. Results last approximately 6–12 months depending on the individual.
Cost
Pricing varies by market, product, and clinic:
- UK and Europe: £200–£400 per session; €250–€500 per session
- Asia-Pacific markets: $200–$500 per session depending on product and country
- Markets where available: A full course of 3–4 sessions typically costs $800–$2,000
Polynucleotides are generally comparable in per-session cost to Profhilo and less expensive per session than HA filler treatments, though the multi-session protocol means the total course investment is meaningful.
Polynucleotides vs PRP vs exosomes
| Feature | Polynucleotides | PRP (Platelet-Rich Plasma) | Exosomes |
|---|---|---|---|
| Source | Purified salmon DNA | Patient's own blood | Lab-processed cell cultures |
| Mechanism | Fibroblast activation, ECM remodeling, anti-inflammatory | Growth factor release from platelets | Cell-signaling vesicles |
| Standardization | Standardized pharmaceutical product | Variable (depends on patient blood quality) | Highly variable (no standardization) |
| Sessions | 3–4, spaced 2–3 weeks | 3–6, spaced 4–6 weeks | Varies by protocol |
| Duration | 6–12 months | 3–6 months | Under research |
| Regulatory | CE-marked medical devices in EU; no FDA approval in US | Minimal regulation (autologous) | Regulatory grey zone |
Polynucleotides offer more consistency than PRP because the product is pharmaceutical-grade and standardized, rather than dependent on individual patient blood quality. Compared to exosomes, polynucleotides have a longer clinical track record and clearer regulatory status in most markets.
Who is a good candidate
Polynucleotides work best for:
- Patients with mild to moderate skin aging seeking texture and quality improvement
- Periorbital rejuvenation where fillers are risky
- Neck and decollete skin quality improvement
- Patients with inflammatory skin conditions who need anti-inflammatory as well as regenerative effects
- Those wanting natural-looking results without volume change
- Skin preparation before or after more aggressive procedures (lasers, deep peels)
Limitations:
- No volumizing effect — patients needing volume restoration should consider fillers or biostimulators
- Results are gradual, not immediate
- Not a substitute for surgical intervention in cases of significant laxity
- Not available in the United States (no FDA approval)
- Multiple sessions required, which increases total cost and time commitment
The "primer" role in combination treatments
A growing trend in 2026 is using polynucleotides as a tissue-conditioning "primer" before other treatments. Clinics are reporting that pre-treating skin with polynucleotides before energy-based devices (RF microneedling, fractional laser) or filler placement improves healing response, tissue resilience, and overall outcomes. This tissue-first approach — regenerating the canvas before painting on it — reflects a broader shift in aesthetic medicine away from isolated corrections and toward comprehensive skin health.
Sources
A real-life assessment of injectable polynucleotides high purification technology in aesthetic medicine for skin rejuvenation. J Cosmet Dermatol. 2026;25(1):e70532. https://pmc.ncbi.nlm.nih.gov/articles/PMC12759169
Polynucleotides in aesthetic medicine: a review of current practices and perceived effectiveness. PMC. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11311621
Lee YB, Kim JE, Park EJ, Bae MI, Kim DS. Efficacy and safety of a polynucleotide injection for periorbital rejuvenation. J Cosmet Dermatol. 2020;19(9):2275–2280. https://pubmed.ncbi.nlm.nih.gov/32320406
Kim JE, et al. Effects of polynucleotide dermal filler in the correction of crow's feet using an Antera three-dimensional camera. Aesthetic Plast Surg. 2022;46(3):1244–1251. https://pubmed.ncbi.nlm.nih.gov/35357558
Lis R, et al. Polynucleotide injections for neck skin aging: comparison of dosing regimens. Case study comparing single high-dose vs multiple low-dose protocols.
